Theodore Karrison to Survival Analysis
This is a "connection" page, showing publications Theodore Karrison has written about Survival Analysis.
Connection Strength
1.783
-
Nonparametric inference in the accelerated failure time model using restricted means. Lifetime Data Anal. 2022 01; 28(1):23-39.
Score: 0.561
-
Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials? Clin Trials. 2018 04; 15(2):178-188.
Score: 0.429
-
Non-parametric estimators of hazard ratios for comparing two survival curves. Biometrics. 2025 Apr 02; 81(2).
Score: 0.175
-
Scaling and interpreting treatment effects in clinical trials using restricted mean survival time. Clin Trials. 2025 Feb; 22(1):3-10.
Score: 0.166
-
Use of Irwin's restricted mean as an index for comparing survival in different treatment groups--interpretation and power considerations. Control Clin Trials. 1997 Apr; 18(2):151-67.
Score: 0.101
-
Confidence intervals for median survival times under a piecewise exponential model with proportional hazards covariate effects. Stat Med. 1996 Jan 30; 15(2):171-82.
Score: 0.093
-
Comparison of median survival times with adjustment for covariates. Stat Med. 1995 Dec 15; 14(23):2537-53.
Score: 0.092
-
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Cancer. 2020 05 15; 126(10):2146-2152.
Score: 0.031
-
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer. 2019 05 15; 125(10):1629-1636.
Score: 0.028
-
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. PLoS One. 2013; 8(7):e67668.
Score: 0.019
-
A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. Am J Clin Oncol. 2011 Apr; 34(2):150-4.
Score: 0.017
-
Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2010 Oct; 28(5):677-83.
Score: 0.015
-
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
Score: 0.014
-
Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol. 2007 Feb; 127(2):197-205.
Score: 0.012
-
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22.
Score: 0.011
-
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer. 2004 Jan 01; 100(1):65-71.
Score: 0.010
-
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003 Jul 01; 102(1):43-52.
Score: 0.009